Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Avadel Pharmaceuticals plc’s stock clocked out at $17.97, up 0.90% from its previous closing price of $17.81. In other words, the price has increased by $0.90 from its previous closing price. On the day, 0.55 million shares were traded. AVDL stock price reached its highest trading level at $18.26 during the session, while it also had its lowest trading level at $17.82.
Ratios:
To gain a deeper understanding of AVDL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.36 and its Current Ratio is at 3.64. In the meantime, Its Debt-to-Equity ratio is 0.40 whereas as Long-Term Debt/Eq ratio is at 0.39.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on March 05, 2024, Reiterated its Outperform rating but revised its target price to $29 from $27 previously.
On March 05, 2024, Needham reiterated its Buy rating and also lowered its target price recommendation from $20 to $22.
H.C. Wainwright reiterated its Buy rating for the stock on March 05, 2024, while the target price for the stock was revised from $21 to $25.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 16 ’24 when MCHUGH THOMAS S bought 2,000 shares for $14.50 per share. The transaction valued at 29,000 led to the insider holds 80,500 shares of the business.
McCamish Mark Anthony sold 75,000 shares of AVDL for $1,089,750 on Dec 28 ’23. The Director now owns 67,025 shares after completing the transaction at $14.53 per share. On Aug 14 ’23, another insider, MCHUGH THOMAS S, who serves as the Chief Financial Officer of the company, bought 2,000 shares for $14.45 each. As a result, the insider paid 28,900 and bolstered with 78,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVDL now has a Market Capitalization of 1627668608 and an Enterprise Value of 1557993600. For the stock, the TTM Price-to-Sale (P/S) ratio is 61.07 while its Price-to-Book (P/B) ratio in mrq is 19.47. Its current Enterprise Value per Revenue stands at 55.716 whereas that against EBITDA is -11.449.
Stock Price History:
The Beta on a monthly basis for AVDL is 1.62, which has changed by 0.34808707 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, AVDL has reached a high of $18.85, while it has fallen to a 52-week low of $9.50. The 50-Day Moving Average of the stock is 13.06%, while the 200-Day Moving Average is calculated to be 31.83%.
Shares Statistics:
It appears that AVDL traded 1.20M shares on average per day over the past three months and 1040340 shares per day over the past ten days. A total of 89.83M shares are outstanding, with a floating share count of 80.25M. Insiders hold about 25.65% of the company’s shares, while institutions hold 52.82% stake in the company. Shares short for AVDL as of 1713139200 were 10613205 with a Short Ratio of 8.63, compared to 1710460800 on 10474142. Therefore, it implies a Short% of Shares Outstanding of 10613205 and a Short% of Float of 11.81.
Earnings Estimates
A comprehensive evaluation of Avadel Pharmaceuticals plc (AVDL) is underway, with the input of 9.0 analysts contributing to its current rating.On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.02 and a low estimate of -$0.31, while EPS last year was -$0.48. The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.02 and low estimates of -$0.17.
Analysts are recommending an EPS of between -$0.05 and -$1.02 for the fiscal current year, implying an average EPS of -$0.4. EPS for the following year is $1.03, with 7.0 analysts recommending between $2.45 and $0.34.
Revenue Estimates
For the next quarter, 9 analysts are estimating revenue of $36.61M. There is a high estimate of $43.62M for the next quarter, whereas the lowest estimate is $33.5M.
A total of 9 analysts have provided revenue estimates for AVDL’s current fiscal year. The highest revenue estimate was $176.8M, while the lowest revenue estimate was $146.5M, resulting in an average revenue estimate of $162.23M. In the same quarter a year ago, actual revenue was $27.96MBased on 7 analysts’ estimates, the company’s revenue will be $293.04M in the next fiscal year. The high estimate is $334.2M and the low estimate is $248M.
